15011-26-4

Basic information

• Product Name: N-(2-methylquinolin-8-yl)benzenesulfonamide
• Synonyms: benzenesulfonamide, N-(2-methyl-8-quinolinyl)-; N-(2-Methylquinolin-8-yl)benzenesulfonamide
• CAS NO: 15011-26-4
• Molecular Formula: C₁₆H₁₄N₂O₂S
• Molecular Weight: 298.3596
• Mol File: 15011-26-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 486.4°C at 760 mmHg
• Flash Point: 248°C
• Density: 1.342g/cm³
• Vapor Pressure: 1.29E-09mmHg at 25°C
• Refractive Index: 1.679
• CAS DataBase Reference: N-(2-methylquinolin-8-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-methylquinolin-8-yl)benzenesulfonamide(15011-26-4)
• EPA Substance Registry System: N-(2-methylquinolin-8-yl)benzenesulfonamide(15011-26-4)

Safety Data

• Hazardous Substances Data: 15011-26-4(Hazardous Substances Data)

Upstream product

• 18978-78-4 2-methyl-8-aminoquinoline 
• 98-09-9 benzenesulfonyl chloride 
• 881-07-2 8-nitroquinaldine 

Downstream Products

• 443987-86-8 8-benzenesulfonamido-2-quinolinecarboxaldehyde 
• 1051379-58-8 5-(4-nitrobenzenediazo)-8-benzenesulfonamidoquinaldine 

Relevant articles and documents

Metal-Binding Pharmacophore Library Yields the Discovery of a Glyoxalase 1 Inhibitor

Anxiety and depression are common, highly comorbid psychiatric diseases that account for a large proportion of worldwide medical disability. Glyoxalase 1 (GLO1) has been identified as a possible target for the treatment of anxiety and depression. GLO1 is a Zn2+-dependent enzyme that isomerizes a hemithioacetal, formed from glutathione and methylglyoxal, to a lactic acid thioester. To develop active inhibitors of GLO1, fragment-based drug discovery was used to identify fragments that could serve as core scaffolds for lead development. After screening a focused library of metal-binding pharmacophores, 8-(methylsulfonylamino)quinoline (8-MSQ) was identified as a hit. Through computational modeling and synthetic elaboration, a potent GLO1 inhibitor was developed with a novel sulfonamide core pharmacophore. A lead compound was demonstrated to penetrate the blood-brain barrier, elevate levels of methylglyoxal in the brain, and reduce depression-like behavior in mice. These findings provide the basis for GLO1 inhibitors to treat depression and related psychiatric illnesses.

Antihypertensive Effects of 5-(4-Nitrobenzenediazo)-8- benzenesulfonamidoquinaldine in spontaneously hypertensive rats

-

The synthesis of azacrown ethers with quinoline-based sidearms as potential zinc(II) fluorophores

Two novel fluorophores, 12 and 13, composed of diaza-18-crown-6 ligands containing two quinoline-based sidearms which are structurally similar to Zn(II) fluorophores TSQ (1) and Zinquin (2) were synthesized as potential Zn(II) fluorophores by reductive amination of 8-benzenesulfonamido-2-quinoline carboxaldehyde 6 and 8-benzenesulfonamido-6-quinolyloxyacetate-2-carboxaldehyde 11 with diaza-18-crown-6 using sodium triacetoxyborohydride (NaBH(OAc)3) as the reducing agent. Preliminary photophysical properties of ligands 12 and 13 show that they possess the properties necessary to be effective chemosensors for Zn2+. The solid state structure of 12 is also reported.